Volker Germaschewski
27Patents
6h-index
59Co-inventors
68Inventor score
Filing activity: Aug 5, 2003 → Apr 28, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9567399B1 | Antibodies and immunocytokines | Chemistry; Metallurgy | 62 | Active |
| US9617338B1 | Antibodies and immunocytokines | Chemistry; Metallurgy | 61 | Active |
| US10604576B2 | Antibodies and immunocytokines | Chemistry; Metallurgy | 17 | Active |
| US7612183B2 | Humanised anti-mag antibody or functional fragment thereof | Chemistry; Metallurgy | 15 | Expired |
| US9957323B2 | Anti-ICOS antibodies | Chemistry; Metallurgy | 14 | Active |
| US10667501B2 | Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins | Chemistry; Metallurgy | 11 | Active |
| US8858943B2 | Antigen binding proteins | Chemistry; Metallurgy | 6 | Active |
| US8227576B2 | Antibodies against amyloid-β peptide | Chemistry; Metallurgy | 4 | Active |
| US7858753B2 | Immunoglobulins | Chemistry; Metallurgy | 4 | Active |
| US8921523B2 | Humanized anti-beta-amyloid antibodies | Chemistry; Metallurgy | 4 | Active |
| US8071731B2 | Humanised anti-MAG antibody or functional fragment thereof | Chemistry; Metallurgy | 2 | Active |
| US10703814B2 | Method of treatment with humanized anti-IL-18 antibodies | Chemistry; Metallurgy | 2 | Active |
| US8133978B2 | Humanised anti-interleukin-18 antibody | Chemistry; Metallurgy | 2 | Active |
| US8637018B2 | Humanized anti-IL-18 antibodies | Chemistry; Metallurgy | 1 | Active |
| US8496932B2 | Compounds | Chemistry; Metallurgy | 1 | Active |
| US11858996B2 | Anti-ICOS antibodies | Chemistry; Metallurgy | 1 | Active |
| US11965026B2 | Anti-PD-L1 and IL-2 cytokines | Chemistry; Metallurgy | 1 | Active |
| US8828384B2 | Compounds | Chemistry; Metallurgy | 0 | Active |
| US10221234B2 | Antigen binding proteins | Chemistry; Metallurgy | 0 | Active |
| US11440960B2 | TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo | Emerging Cross-Sectional Technologies | 0 | Active |
| US11648308B2 | Methods, regimens, combinations and antagonists | Chemistry; Metallurgy | 0 | Active |
| US12209128B2 | Anti-PD-L1 antibodies | Chemistry; Metallurgy | 0 | Active |
| US8974782B2 | Treatment of stroke comprising anti-MAG antibodies | Emerging Cross-Sectional Technologies | 0 | Active |
| US8362208B2 | Immunoglobulins | Chemistry; Metallurgy | 0 | Active |
| US9499617B2 | Humanized anti-IL-18 antibodies | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.